MedTrace Logo

Biochemical Profiling of Migraine Patients

NCT06549270 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-09-05

No results posted yet for this study

Summary

Aim of the study was to assess a potential dysfunction of the endocannabidiome system (eCBome) in migraine patients. Migraine patients who will undergo preventive therapy with monoclonal antibodies directed against the calcitonin gene related peptide (mAbs) will be evaluated through a deep phenotyping of peripheral neurochemical biomarkers (eCBome, neuropeptides, cytokines and kynurenine levels, and microRNAs expression).

Primary aim is to assess baseline differences among those patients who achieved a reduction of monthly migraine days \>/= 50% after three months of tretament (namely Responders) and those who did not (namely Non-responders).

Conditions

  • Migraine Disorders
  • Chronic Migraine
  • Episodic Migraine

Interventions

DRUG

MAbs

Monthly or quarterly mAbs administration

Sponsors & Collaborators

  • University of L'Aquila

    collaborator OTHER

  • IRCCS National Neurological Institute "C. Mondino" Foundation

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2026-02-28
Completion
2026-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549270 on ClinicalTrials.gov